Novartis Pelacarsen Fails Phase 3 CV Outcomes Trial, Ionis's Second Miss in 57 Days
Pipeline Setback
Company Background
Ionis Pharmaceuticals is a Carlsbad-based RNA-targeted drug maker with three marketed medicines: TRYNGOLZA (olezarsen) for severe hypertriglyceridemia and familial chylomicronemia syndrome, DAWNZERA (donidalorsen) for hereditary angioedema, and ZANVASTRO (zilganersen), which the FDA approved on September 3, 2026 for Alexander disease. The company also earns royalties on SPINRAZA (nusinersen, spinal muscular atrophy) and WAINUA (eplontersen, hereditary ATTR polyneuropathy), which together contributed $134 million in royalties through the first half of 2026.
Revenue in the first half of 2026 was $514 million on a GAAP operating loss of $220 million. Cash and short-term investments stood at $2.1 billion as of June 30, 2026, down from $2.7 billion at year-end 2025 primarily after repaying $633 million in convertible notes due April 1, 2026. The company carries $753 million in 0% convertible notes due 2030 and $569 million in 1.75% convertible notes due 2028. Management has consistently guided toward cash-flow breakeven in 2028, driven by growing commercial product revenue.
In April 2026, Ionis raised its long-term peak sales guidance for olezarsen to greater than $3 billion, up from greater than $2 billion, citing confidence in the severe hypertriglyceridemia market. Pelacarsen appeared in the company's own 2026 milestones table as a planned U.S. regulatory submission — a milestone that is now extinguished.
What Was Disclosed
Novartis's pelacarsen Phase 3 Lp(a)HORIZON study, which enrolled 8,323 patients with elevated lipoprotein(a) levels and established cardiovascular disease, did not meet its primary endpoint of reducing major adverse cardiovascular events compared to placebo. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization requiring hospitalization. The trial evaluated patients in both an overall population with Lp(a) of at least 70 mg/dL and a subpopulation with Lp(a) of at least 90 mg/dL. All study participants received guideline-directed therapies including lipid-lowering and antihypertensive treatments.